Study of how patients stick with cholesterol-lowering injection medications
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study follows people who are starting one of three injectable cholesterol medications (inclisiran, evolocumab, or alirocumab) to see how well they stick with treatment over time. Understanding medication adherence helps doctors and patients find ways to improve long-term health outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You received your first-ever injection of inclisiran, evolocumab, or alirocumab during a specific time period
- Your healthcare provider has medical records for you going back at least 12 months before starting the injection
- You have not previously received both evolocumab and alirocumab before starting your current medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how consistently people take their cholesterol-lowering injections (inclisiran or evolocumab) in real life. It may help doctors understand what makes it easier or harder to stick with these medicines.
This study looks at how well people stick with and respond to the cholesterol-lowering drug Inclisiran. It aims to understand if the medicine works well over time in Italian patients.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study tests a new injectable medicine called inclisiran for people who are already on many medications and have high cholesterol. It is designed for those who cannot lower their cholesterol enough with statins, especially if they have diabetes or other heart risks.
This study tracks how well patients stick to and benefit from alirocumab 300mg, a cholesterol-lowering injection. It looks at real-world use in Italy.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
Hear when a new Cardiovascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.